Markets
    Venture Capital

    Boston Medical Sciences Raises 5.55 Billion Yen for Laxative-Free AI Colon Cancer Scans

    The Tokyo medical AI startup, founded by Harvard-affiliated doctors, drew Nomura SPARX, Global Brain and Beyond Next Ventures as co-leads as it moves toward Japanese approval and a U.S. push.

    Share on X LinkedIn WhatsApp
    Positioning lasers on a computed tomography scanner
    Positioning lasers on a CT scanner. Photo: Daniel Sone (Photographer) via Wikimedia Commons, Public domain

    What to know

    • Boston Medical Sciences raised 5.55 billion yen in a Series B share sale co-led by a Nomura SPARX-managed fund, Global Brain and Beyond Next Ventures, it said on Nov. 13.
    • Its laxative-free virtual colonoscopy system, AIM4CRC, has completed domestic clinical trials in Japan and received FDA Breakthrough Device designation in May, but is not approved in either country.
    • Global Brain also led a pre-Series A of about 910 million yen in Space Quarters, a Tohoku University spinout building robots that weld structures in orbit.

    TOKYO

    Boston Medical Sciences, a Tokyo startup developing an AI system that screens for colorectal cancer from CT scans without the laxatives a colonoscopy requires, said it raised 5.55 billion yen in a Series B round. The money came through a third-party allotment of new shares, the company said in a statement on Nov. 13.

    Three investors co-led the round: Nippon Growth Capital Investment Corp., whose assets are managed by Nomura SPARX Investment, plus Tokyo venture firms Global Brain and Beyond Next Ventures. The deal is about six times the 930 million yen the company raised in its Series A in February 2025, and it comes before the company's product has won regulatory approval in any market.

    Who is backing Boston Medical Sciences

    Global Brain invested through five vehicles, it said in a separate release: its Takanawa Gateway fund, a fund run with Meiji Yasuda, its ninth flagship fund, TOHO Ventures and a corporate venture fund with Fukoku. The last three are investing in the company for the first time. Global Brain announced earlier investments in the company in October 2024 and February 2025, so this is its third.

    Beyond Next Ventures has taken part in every round since the company was founded, according to BRIDGE, a Tokyo startup news site, which also reported that Aflac Ventures Japan joined the Series B. The Series A had brought in JIC Venture Growth Investments, Mitsubishi UFJ Capital and a fund set up by East Japan Railway and Global Brain, BRIDGE reported at the time.

    The company did not disclose a valuation. Its website lists 47 employees as of Nov. 1.

    Physicians who teach or do research at Harvard Medical School and Massachusetts General Hospital founded Boston Medical Sciences in April 2023. Despite the name, it is headquartered in Tokyo's Chuo ward. Chief Executive Masaki Okamoto said in the statement that he treated the size of the raise as a responsibility to move development and the business forward, and that the company wanted to take a technology grown in Japan to the rest of the world.

    AIM4CRC: trials done, approval still pending

    The product, which the company calls a laxative-free virtual endoscope and BRIDGE identifies as AIM4CRC, combines three pieces: AI that digitally "cleans" the bowel in CT images, AI that helps doctors spot polyps, and image reconstruction software. The core technology is patent-pending, BRIDGE reported. The pitch is simple. Many people skip follow-up colon exams because they involve drinking large volumes of laxative and having a scope inserted, and a CT-based test without that preparation could lower the barrier.

    In Japan, the health ministry designated the software for priority review under its program for software medical devices, and the company has completed domestic clinical trials. In the United States, the Food and Drug Administration granted it Breakthrough Device designation in May 2026, and in June it was accepted into the FDA's TAP pilot, which allows close consultation with the agency from early in development.

    The company stressed that none of these steps amounts to marketing approval or certification. The system is unapproved in both Japan and the United States, Global Brain's release said.

    The new money will go to research and clinical evidence, regulatory work in both countries, preparing hospital partnerships, quality assurance and hiring for a domestic launch after approval, and business development with medical institutions and partners, mainly in the United States. The company already runs joint research with the 3D Imaging Research group at Harvard Medical School and Massachusetts General Hospital and the National Cancer Center Hospital in Tokyo, and in June began joint work on CT-screening AI with the Tokushukai hospital group.

    A Nomura SPARX principal said in the statement that Japan's colorectal cancer screening rate tends to be low compared with other countries, and that the product could spread to global markets. A Beyond Next Ventures partner noted the company finished domestic trials three and a half years after its founding.

    Global Brain also leads a space round

    Global Brain's ninth fund also led a pre-Series A of about 910 million yen in Space Quarters, a Tohoku University spinout founded in June 2022 that develops robots to assemble and electron-beam weld large structures in orbit and on the moon, BRIDGE reported on Monday. The firm also invested through corporate venture funds it runs with Tokyu Construction, ANA and Canon Marketing Japan, and the company's cumulative funding since its angel round is about 1.82 billion yen. It has a contract with Space BD to demonstrate welding and X-ray inspection outside Japan's Kibo module on the International Space Station in 2028, according to BRIDGE.

    Separately, NearMe, which runs an AI-matched shared taxi service, said on Nov. 12 it raised about 520 million yen in equity and loans, with venture capital arms of four regional financial groups as new investors, a follow-on investment from JIC Venture Growth Investments and an additional loan from Japan Finance Corp., BRIDGE reported. Its cumulative funding is about 3.88 billion yen.

    The rounds follow other large Japanese raises this autumn, including Knowledge Work's Series C, and Capital Times has also reported on Allganize's Tokyo debut. For Boston Medical Sciences, the next marker is a regulatory one: a Japanese approval decision on AIM4CRC, for which the company has not given a date.

    Sources

    1. Boston Medical Sciences (PR TIMES): Boston Medical Sciences - シリーズBラウンドで55.5億円をエクイティ調達 (Nov. 13, 2026)
    2. Global Brain: 無下剤のAI大腸がんスクリーニングシステムを開発するBoston Medical Sciences株式会社へコリードインベスターとして追加出資 (Nov. 13, 2026)
    3. BRIDGE: 下剤のいらない大腸CT検査のAIを開発するBoston Medical Sciences、シリーズBで55.5億円を調達 (Nov. 16, 2026)
    4. BRIDGE: 下剤不要のバーチャル内視鏡検査システムを開発: Boston Medical Sciencesが9.3億円をシリーズA調達、国内外の事業展開へ体制強化 (Feb. 19, 2025)
    5. Boston Medical Sciences: 企業情報 (Nov. 17, 2026)
    6. BRIDGE: 軌道上で溶接して宇宙の構造物を組み立てるSpace Quarters、プレシリーズAで9.1億円を調達 (Nov. 16, 2026)
    7. BRIDGE: 相乗りタクシーや空港送迎のNearMe、5.2億円を調達 (Nov. 13, 2026)

    Capital Times Staff

    Capital Times newsroom, Hong Kong, Singapore and Jakarta

    Capital Times covers markets, business and economies across Asia.

    newsroom@capitaltimes.asia

    Our standards: Capital Times reports under the principles set out in our Editorial Standards and Ethics Policy. Spotted an error? Report it to our editors.

    Markets Data

    Hong Kong ClosedShanghai ClosedTokyo OpenSeoul OpenSingapore OpenJakarta ClosedSydney OpenMumbai Closed